Zacks Investment Research downgraded shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from a hold rating to a sell rating in a research report report published on Wednesday morning.

According to Zacks, “Although Teva is working on the integration of Actavis Generics and progressing with its branded pipeline, headwinds persist in the form of generic competition for Copaxone, as well as competition for branded products. Meanwhile, the generics segment could remain under pressure due to pricing erosion as well as the absence of important new product launches. However, the Actavis Generics acquisition will help Teva strengthen its position in key generic markets. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. Meanwhile, Teva intends to accelerate growth platforms, protect and expand core franchises, expand its global presence, pursue strategic deals and reduce the cost base. Estimates have been going down ahead of the company’s Q3 earnings release. The company has a positive record of earnings surprises in recent quarters.”

A number of other research firms have also recently commented on TEVA. Mizuho reaffirmed a buy rating and issued a $70.00 price target (down previously from $75.00) on shares of Teva Pharmaceutical Industries in a report on Friday, August 5th. Goldman Sachs Group Inc. cut shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and lowered their price target for the stock from $70.00 to $60.00 in a report on Friday, July 15th. Guggenheim reaffirmed a buy rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. Leerink Swann reaffirmed an outperform rating and issued a $66.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Finally, Jefferies Group lowered their price target on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a buy rating on the stock in a report on Thursday, July 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries presently has a consensus rating of Buy and an average price target of $66.98.

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded up 0.66% during midday trading on Wednesday, hitting $44.41. The company’s stock had a trading volume of 2,366,078 shares. The stock’s 50 day moving average is $49.32 and its 200-day moving average is $52.31. The firm has a market cap of $40.59 billion, a P/E ratio of 29.67 and a beta of 0.74. Teva Pharmaceutical Industries has a 52-week low of $43.80 and a 52-week high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.05. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.86 billion. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. Teva Pharmaceutical Industries’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.43 EPS. Equities analysts predict that Teva Pharmaceutical Industries will post $5.24 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Krilogy Financial LLC increased its stake in shares of Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock worth $132,000 after buying an additional 25 shares in the last quarter. Veritable L.P. increased its stake in shares of Teva Pharmaceutical Industries by 0.5% in the second quarter. Veritable L.P. now owns 5,216 shares of the company’s stock worth $262,000 after buying an additional 26 shares in the last quarter. Toronto Dominion Bank increased its stake in shares of Teva Pharmaceutical Industries by 0.6% in the second quarter. Toronto Dominion Bank now owns 6,025 shares of the company’s stock worth $304,000 after buying an additional 35 shares in the last quarter. Trust Co increased its stake in shares of Teva Pharmaceutical Industries by 0.3% in the first quarter. Trust Co now owns 13,980 shares of the company’s stock worth $748,000 after buying an additional 40 shares in the last quarter. Finally, WESPAC Advisors SoCal LLC increased its stake in shares of Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock worth $178,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 63.35% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.